

LETTERS  
TO THE EDITOR

## Synthesis of 9-Aryl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-ones

V. L. Gein<sup>a</sup>, M. I. Kazantseva<sup>b</sup>, T. M. Zamaraeva<sup>a</sup>, L. F. Gein<sup>b</sup>, and P. A. Slepukhin<sup>c</sup>

<sup>a</sup> Perm State Pharmaceutical Academy of the Ministry of Health of the Russian Federation,  
ul. Plevaya 2, Perm, 614990 Russia  
e-mail: geinvl48@mail.ru

<sup>b</sup> Perm State Medical University, Perm, Russia

<sup>c</sup> Postovskii Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, Yekaterinburg, Russia

Received April 2, 2015

**Keywords:** three-component reaction, 1,3-cyclohexanedione, dimedone, aromatic aldehyde, 5-aminotetrazole monohydrate, 9-aryl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one

**DOI:** 10.1134/S1070363215080332

It has been earlier found that the reaction of keto acids esters with a mixture of an aromatic aldehyde and 5-aminotetrazole leads to the formation of fused heterocyclic systems [1]. Reaction of methyl esters of acylpyruvic acids with 5-aminotetrazole in the presence of an aromatic aldehyde has yielded 5-aryl-6-acyl-7-methoxycarbonyl-5,8-dihydrotetrazolo[1,5-*a*]pyrimidines [2]. The reaction with 3-amino-1,2,4-triazole proceeds similarly to give 4-aryl-3-benzoyl-2-methoxycarbonyl-1,4-dihydropyrimidino[1,2-*d*]tetrazoles [3]. It has been found that the fusion of various acetylacetates with a mixture of aromatic aldehyde and 5-aminotetrazole affords dihydrotetrazolo[1,5-*a*]pyrimidine derivatives [4], being the only reaction product when using *N*-substituted amides of acetylacetic acid as the dicarbonyl compound [5]. 5-Aminotetrazole is known to be a part of certain drugs such as korazol, cefazolin, and cefoperazonum [6].


Aiming to synthesize new heterocyclic compounds with potential biological activity containing 5-aminotetrazole fragment, we used 1,3-cyclohexanedione and dimedone as the dicarbonyl components instead of esters of acetylacetic and acylpyruvic acids.

Reaction of equimolar amounts of 1,3-cyclohexanedione or dimedone, an aromatic aldehyde, and 5-aminotetrazole monohydrate in bulk at 160–170°C during 10–12 min gave 9-aryl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-ones **I–IV** and 9-aryl-6,6-dimethyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-ones **V–VIII** (Scheme 1).

The resulting compounds **I–VIII** were pale-yellow crystalline solids, soluble in ethanol, and insoluble in water.

IR spectra of compounds **I–VIII** contained absorption bands assigned to stretching of the C=C (1580–

Scheme 1.



R<sup>1</sup> = H, R<sup>2</sup> = H (**I**), 4-Cl (**II**), 4-MeO (**III**), 4-NO<sub>2</sub> (**IV**); R<sup>1</sup> = Me, R<sup>2</sup> = H (**V**), 4-Cl (**VI**), 4-OMe (**VII**), 4-NO<sub>2</sub> (**VIII**).


1588  $\text{cm}^{-1}$ ), C=O (1641–1654  $\text{cm}^{-1}$ ), and N–H bonds (3251–3290  $\text{cm}^{-1}$ ).

$^1\text{H}$  NMR spectra of compounds **V–VIII** contained the signals of aromatic fragments and related groups along with the following characteristic signals: two singlets of two methyl groups in position 6 at 0.80–0.83 and 1.02–1.04 ppm, four doublets of the protons  $\text{H}^5$  and  $\text{H}^7$  at 1.87–1.90, 2.04–2.06, 2.20–2.23, and 2.35–2.37 ppm, the signal of the  $\text{H}^9$  proton at 6.39–6.65 ppm, and the signal of NH group at 11.40–11.89 ppm. The spectra of compounds **I–IV** contained multiplets of the methylene protons in position 6 (1.70–1.78 ppm) and of protons at positions 5 (1.83–1.92 ppm) and 7 (2.11–2.25 ppm).

To determine the spatial structure of the obtained compounds, we performed X-ray diffraction analysis of crystal of compound **I** grown via slow crystallization from dioxane (see figure). The results were fully consistent with the proposed structure. According to the XRD analysis, compound **I** crystallized as a 1 : 1 solvate with 1,4-dioxane. Most of the bond lengths and bond angles were close to the normal values. The deviations were as follows. The formal single bond  $\text{C}^3\text{--C}^4$  was shortened to 1.461 Å due to the effect of conjugation in the vinyl ketone moiety and the expected alignment of the bond lengths of the tetrazole ring. Cyclohexene ring had a *sofa* conformation, and  $\text{C}^6$  atom was out of the ring plane. The molecules formed dimers in the crystal, due to the paired intermolecular hydrogen bonding  $\text{NH}\cdots\text{N}$  between NH group of the pyrimidine moiety and the  $\text{N}^4$  atom of the tetrazole ring.

**9-Phenyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (I) (general procedure).** A mixture of 1.12 g (0.01 mol) of 1,3-cyclohexanedione, 1.06 mL (0.01 mol) of benzaldehyde, and 1.03 g (0.01 mol) of 5-aminotetrazole monohydrate was incubated during 10–12 min at 160–170°C until the evolution of water vapor ceased, and the reaction mixture solidified. After cooling, the residue was treated with ethanol; the resulting crystals were filtered off and dried. Yield 2.2 g (62%), mp 234–236°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1580 (C=C), 1648 (C=O), 3280 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.70–1.76 m (2H,  $\text{C}^6\text{H}_2$ ), 1.85–1.92 m (2H,  $\text{C}^5\text{H}_2$ ), 2.15–2.25 m (2H,  $\text{C}^7\text{H}_2$ ), 6.46 s (1H,  $\text{C}^9\text{H}$ ), 7.03–7.30 m (5H,  $\text{C}_6\text{H}_5$ ), 11.40 s (1H, NH). Found, %: C 62.77; H 4.62; N 26.49.  $\text{C}_{14}\text{H}_{13}\text{N}_5\text{O}$ . Calculated, %: C 62.91; H 4.90; N 26.20. *M* 267.29.

Compounds **II–VIII** were obtained similarly.



General view of the molecule of compound **I**.

**9-(4-Chlorophenyl)-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (II).** Yield 2.9 g (68%), mp 245–247°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1584 (C=C), 1646 (C=O), 3288 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.73–1.76 m (2H,  $\text{C}^6\text{H}_2$ ), 1.85–1.92 m (2H,  $\text{C}^5\text{H}_2$ ), 2.11–2.25 m (2H,  $\text{C}^7\text{H}_2$ ), 6.54 s (1H,  $\text{C}^9\text{H}$ ), 7.10 s (4H,  $\text{C}_6\text{H}_4\text{Cl}$ ), 11.60 s (1H, NH). Found, %: C 55.57; H 4.32; N 23.43.  $\text{C}_{14}\text{H}_{12}\text{ClN}_5\text{O}$ . Calculated, %: C 55.73; H 4.01; N 23.21. *M* 301.74.

**9-(4-Methoxyphenyl)-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (III).** Yield 2.4 g (64%), mp 215–218°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1586 (C=C), 1641 (C=O), 3290 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm (*J*, Hz): 1.70–1.74 m (2H,  $\text{C}^6\text{H}_2$ ), 1.83–1.92 m (2H,  $\text{C}^5\text{H}_2$ ), 2.15–2.25 m (2H,  $\text{C}^7\text{H}_2$ ), 3.65 s (3H,  $\text{C}_6\text{H}_4\text{OCH}_3$ ), 6.43 s (1H,  $\text{C}^9\text{H}$ ), 6.65 d and 7.00 d (4H,  $\text{C}_6\text{H}_4\text{OCH}_3$ , *J* 8.4), 11.50 s (1H, NH). Found, %: C 60.37; H 4.92; N 23.78.  $\text{C}_{15}\text{H}_{15}\text{N}_5\text{O}_2$ . Calculated, %: C 60.60; H 5.09; N 23.55. *M* 297.32.

**9-(4-Nitrophenyl)-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (IV).** Yield 3.2 g (73%), mp 233–235°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1580 (C=C), 1648 (C=O), 3280 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm (*J*, Hz): 1.73–1.78 m (2H,  $\text{C}^6\text{H}_2$ ), 1.83–1.92 m (2H,  $\text{C}^5\text{H}_2$ ), 2.15–2.25 m (2H,  $\text{C}^7\text{H}_2$ ), 6.68 s (1H,  $\text{C}^9\text{H}$ ), 7.73 d and 8.08 d (4H,  $\text{C}_6\text{H}_4\text{NO}_2$ , *J* 9.3), 11.34 s (1H, NH). Found, %: C 53.97; H 3.92; N 26.88.  $\text{C}_{14}\text{H}_{12}\text{N}_6\text{O}_3$ . Calculated, %: C 53.85; H 3.87; N 26.97. *M* 312.30.

**9-Phenyl-6,6-dimethyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (V).** Yield 2.78 g (68%),

mp 196–198°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1588 (C=C), 1652 (C=O), 3256 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 0.80 s and 1.02 s (6H,  $\text{CH}_3$ ), 1.90 d (1H,  $\text{H}_\text{A}^5$ ,  $J$  16.1), 2.06 d (1H,  $\text{H}_\text{B}^5$ ,  $J$  16.1), 2.23 d (1H,  $\text{H}_\text{A}^7$ ,  $J$  16.0), 2.37 d (1H,  $\text{H}_\text{B}^7$ ,  $J$  16.1), 6.64 s (1H,  $\text{C}^9\text{H}$ ), 6.85–7.23 m (5H,  $\text{C}_6\text{H}_5$ ), 11.46 s (1H, NH). Found, %: C 65.28; H 5.52; N 23.85.  $\text{C}_{16}\text{H}_{17}\text{N}_5\text{O}$ . Calculated, %: C 65.07; H 5.80; N 23.71.  $M$  295.34.

**9-(4-Chlorophenyl)-6,6-dimethyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (VI).** Yield 3.28 g (74%), mp 193–195°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1581 (C=C), 1650 (C=O), 3258 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 0.83 s and 1.02 s (6H,  $\text{CH}_3$ ), 1.87 d (1H,  $\text{H}_\text{A}^5$ ,  $J$  16.1), 2.06 d (1H,  $\text{H}_\text{B}^5$ ,  $J$  16.1), 2.20 d (1H,  $\text{H}_\text{A}^7$ ,  $J$  16.0), 2.37 d (1H,  $\text{H}_\text{B}^7$ ,  $J$  16.1), 6.56 s (1H,  $\text{C}^9\text{H}$ ), 6.90 d and 7.21 d (4H,  $\text{C}_6\text{H}_4\text{Cl}$ ,  $J$  7.5), 11.67 s (1H, NH). Found, %: C 58.48; H 4.62; N 21.15.  $\text{C}_{16}\text{H}_{16}\text{ClN}_5\text{O}$ . Calculated, %: C 58.27; H 4.89; N 21.23.  $M$  329.79.

**9-(4-Methoxyphenyl)-6,6-dimethyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (VII).** Yield 3.32 g (76%), mp 183–185°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1585 (C=C), 1654 (C=O), 3251 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 0.82 s and 1.02 s (6H,  $\text{CH}_3$ ), 1.87 d (1H,  $\text{H}_\text{A}^5$ ,  $J$  16.1), 2.06 d (1H,  $\text{H}_\text{B}^5$ ,  $J$  16.1), 2.20 d (1H,  $\text{H}_\text{A}^7$ ,  $J$  16.0), 2.35 d (1H,  $\text{H}_\text{B}^7$ ,  $J$  16.1), 3.65 s (3H,  $\text{C}_6\text{H}_4\text{OCH}_3$ ), 6.39 s (1H,  $\text{C}^9\text{H}$ ), 6.77 d and 7.08 d (4H,  $\text{C}_6\text{H}_4\text{OCH}_3$ ,  $J$  8.5), 11.46 s (1H, NH). Found, %: C 62.57; H 5.62; N 21.75.  $\text{C}_{17}\text{H}_{19}\text{N}_5\text{O}_2$ . Calculated, %: C 62.76; H 5.89; N 21.52.  $M$  325.37.

**9-(4-Nitrophenyl)-6,6-dimethyl-5,6,7,9-tetrahydrotetrazolo[5,1-*b*]quinazolin-8(4*H*)-one (VIII).** Yield 3.6 g (79%), mp 180–182°C (EtOH). IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 1588 (C=C), 1654 (C=O), 3256 (N–H).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 0.80 s and 1.02 s (6H,  $\text{CH}_3$ ), 1.87 d (1H,  $\text{H}_\text{A}^5$ ,  $J$  16.1), 2.06 d (1H,  $\text{H}_\text{B}^5$ ,  $J$  16.1), 2.20 d (1H,  $\text{H}_\text{A}^7$ ,  $J$  16.0), 2.35 d (1H,  $\text{H}_\text{B}^7$ ,  $J$  16.1), 6.65 s (1H,  $\text{C}^9\text{H}$ ), 7.85 m and 8.23 m (4H,  $\text{C}_6\text{H}_4\text{NO}_2$ ), 11.89 s (1H, NH). Found, %: C 56.67; H 4.53; N 24.85.  $\text{C}_{16}\text{H}_{16}\text{N}_6\text{O}_3$ . Calculated, %: C 56.47; H 4.74; N 24.69.  $M$  340.35.

IR spectra (mineral oil) were recorded with a Specord M-80 spectrophotometer.  $^1\text{H}$  NMR spectra were registered using a Bruker 500 instrument (500.13 MHz,  $\text{DMSO-}d_6$ ) relative to internal TMS reference. Elemental

analysis was performed with a Perkin Elmer 2400 instrument. Melting points were determined using an M-565 apparatus. X-Ray diffraction analysis was performed with an automated four-circle diffractometer Xcalibur S via the standard procedure [ $\text{MoK}_\alpha$  radiation, 295(2) K,  $\omega/2\theta$ -scanning with step of  $1^\circ$ ]. Solution and refinement of the structure was carried out using SHELXTL software package [7]. Main crystallographic parameters were as follows: triclinic crystal system, space group *P*-1,  $a = 6.1005(8)$ ,  $b = 11.2632(17)$ ,  $c = 12.595(3)$  Å,  $\alpha = 107.36(2)^\circ$ ,  $\beta = 103.928(17)^\circ$ ,  $\gamma = 101.369(12)^\circ$ ,  $\mu = 0.093 \text{ mm}^{-1}$ . 5967 reflections were collected over the range of reflection angles of  $3.11^\circ < \theta < 28.28^\circ$ , 3605 of them being independent ( $R_{\text{int}} 0.0235$ ), including 1531 with  $I > 2\sigma(I)$ ,  $\text{Goof}$  1.004,  $R_1$  0.1085,  $wR_2$  0.0576 (for all reflections),  $\Delta\rho_{\text{e}} = 0.212/-0.188 \text{ e/Å}^{-3}$ .

The XRD data were deposited in the Cambridge Structural Database (CCDC 1,410,335).

## ACKNOWLEDGMENTS

This work was financially supported by the Russian Science Foundation (project no. 15-13-10029).

## REFERENCES

1. Zhidovinova, M.S., Rusinov, G.L., and Ovchinnikova, I.G., *Russ. Chem. Bull.*, 2003, vol. 52, no. 8, p. 1768. DOI: 10.1023/A:1026052603951.
2. Gein, V.L., Tsypliyakova, E.P., Rozova, E.A., and Gein, L.F., *Russ. J. Org. Chem.*, 2003, vol. 39, no. 5, p. 753. DOI: 10.1023/A:1026002522354.
3. Gein, V.L., Gein, L.F., and Tsypliyakova, E.P., *Chem. Heterocycl. Compd.*, 2003, vol. 39, no. 6, p. 821. DOI: 10.1023/A:1025671818256.
4. Gein, V.L., Vladimirov, I.N., Kurbatova, A.A., Nosova, N.V., Krylova, I.V., Vakhrin, M.I., and Fedorova, O.V., *Russ. J. Org. Chem.*, 2010, vol. 46, no. 5, p. 699. DOI: 10.1134/S1070428010050180.
5. Gein, V.L., Zamaraeva, T.M., Zorina, A.A., Levandovskaya, E.B., Nosova, N.V., and Vakhrin, M.I., *Russ. J. Org. Chem.*, 2009, vol. 45, no. 6, p. 942. DOI: 10.1134/S1070428009060256.
6. Mashkovskii, M.D., *Lekarstvennye sredstva* (Drugs), Moscow: Novaya Volna, 2010.
7. Sheldrick, G.M., *Acta Crystallogr. (A)*, 2008, vol. 64, p. 112. DOI: 10.1107/S0108767307043930.